All In Biotech

Drug Trial Radar · NCT00351468

EXTEND (Eltrombopag Extended Dosing Study)

EXTEND (Eltrombopag Extended Dosing Study): An Extension Study of Eltrombopag Olamine (SB-497115-GR) in Adults, With Idiopathic Thrombocytopenic Purpura (ITP), Previously Enrolled in an Eltrombopag Study.

Last checked: Nov 20, 2026Latest source record: Apr 17, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

302

Actual

Start

Jun 2006

Primary completion

Jul 2015

Study completion Jul 2015

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jul 12, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An open-label, dose-adjustment, extension study to evaluate the safety and efficacy of eltrombopag for the treatment of subjects with idiopathic thrombocytopenic purpura (ITP) who have previously been enrolled in an eltrombopag trial. This study will allow adjustment of the eltrombopag dose to achieve an individualized dose and schedule for each subject. In addition, the ability to reduce the dose of concomitant ITP medications in the presence of eltrombopag, while maintaining platelet counts = 50,000/μL will be investigated.

Conditions

  • Purpura, Thrombocytopaenic, Idiopathic

Interventions

  • eltrombopag olamine (SB-497115-GR)Drug

    Eltrombopag with starting dose of 50mg daily, max dose of 75mg daily and min dose of 25mg daily or less frequently. Modifications were given to maintain platelet count in range of 50 to 200 Gi/L.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Summary of On-Therapy Adverse Events (Safety Population)Time frame: Start date was the first dose of investigational product and up to the day after the last dose . Post-therapy: start date was more than 1 day after the last dose and up to 30 days after last dose of investigational product up to week 364

Locations

110 sites in 31 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Huntsville, Alabama

  • Novartis Investigative Site

    Mobile, Alabama

  • Novartis Investigative Site

    Jonesboro, Arkansas

  • Novartis Investigative Site

    Duarte, California

  • Novartis Investigative Site

    Los Angeles, California

  • Novartis Investigative Site

    San Francisco, California

  • Novartis Investigative Site

    Miami, Florida

  • Novartis Investigative Site

    Atlanta, Georgia

  • Novartis Investigative Site

    Savannah, Georgia

  • Novartis Investigative Site

    Peoria, Illinois

  • Novartis Investigative Site

    New Orleans, Louisiana

  • Novartis Investigative Site

    Boston, Massachusetts

  • Novartis Investigative Site

    Detroit, Michigan

  • Novartis Investigative Site

    Brunsville, Minnesota

  • Novartis Investigative Site

    Albuquerque, New Mexico

  • Novartis Investigative Site

    New York, New York

  • Novartis Investigative Site

    Cleveland, Ohio

  • Novartis Investigative Site

    Portland, Oregon

  • Novartis Investigative Site

    Lubbock, Texas

  • Novartis Investigative Site

    Arlington, Virginia

  • Novartis Investigative Site

    Seattle, Washington

  • Novartis Investigative Site

    Tacoma, Washington

  • Novartis Investigative Site

    Vancouver, Washington

  • Novartis investigative Site

    Garran, Australian Capital Territory, Australia

  • Novartis Investigative Site

    Kogarah, New South Wales, Australia

  • Novartis Investigative Site

    Vienna, Austria

  • Novartis Investigative Site

    Hamilton, Ontario, Canada

  • Novartis Investigative Site

    Montreal, Quebec, Canada

  • Novartis Investigative Site

    Montreal, Quebec, Canada

  • Novartis Investigative Site

    Jiang Su Province, China

  • Novartis Investigative Site

    Shanghai, China

  • Novartis Investigative Site

    Tianjin, China

  • Novartis Investigative Site

    Brno, Czechia

  • Novartis Investigative Site

    Olomouc, Czechia

  • Novartis Investigative Site

    Prague, Czechia

  • Novartis Investigative Site

    Odense, Denmark

  • Novartis Investigative Site

    Kuopio, Finland

  • Novartis Investigative Site

    Caen, France

  • Novartis Investigative Site

    Créteil, France

  • Novartis Investigative Site

    Pessac, France

Showing 40 of 110 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.